NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03504488,CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2),https://clinicaltrials.gov/study/NCT03504488,,COMPLETED,The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors,NO,Non Small Cell Lung Cancer|Triple Negative Breast Cancer|Melanoma|Head and Neck Cancer,BIOLOGICAL: CAB-ROR2-ADC|BIOLOGICAL: PD-1 inhibitor,"Phase 1: Safety Profile, Assess dose limiting toxicity as defined in the protocol, Up to 24 months|Phase 1: Safety Profile, Assess maximum tolerated dose as defined in the protocol, Up to 24 months|Phase 1 and 2: Safety Profile, Frequency and severity of AEs and/or SAEs, Up to 24 months|Phase 2: Confirmed Objective Response Rate (ORR), Proportion of patients who achieve a confirmed CR or PR, Up to 24 months","Phase 1: Pharmacokinetics, Plasma concentrations of ADC, total antibody and MMAE, Up to 24 months|Phase 1: Pharmacokinetics, Peak Plasma Concentration (Cmax), Up to 24 months|Phase 1: Pharmacokinetics, Area under the plasma concentration versus time curve, Up to 24 months|Phase 1: Confirmed Objective Response Rate (ORR), Proportion of patients who achieve a confirmed CR or PR, Up to 24 months|Phase 1: Immunogenicity, The number and percentage of patients who develop detectable anti-drug antibodies (ADAs), Up to 24 months|Phase 1 and 2: Duration of response (DOR), Time from the first documented OR until the first documented disease progression or death (due to any cause), whichever occurs first, Up to 24 months|Phase 1 and 2: Progression-free survival (PFS), Time from the first dose of IP until the first documentation of disease progression or death due to any cause, whichever occurs first, Up to 24 months|Phase 1 and 2: Best overall response (OR), All post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy, Up to 24 months|Phase 1 and 2: Disease control rate (DCR), Proportion of patients with a best overall response of confirmed CR, confirmed PR, or stable disease (SD) ≥ 12 weeks, Up to 24 months|Phase 1 and 2: Time to response (TTR), Time from the first dose of investigational product until the first documentation of OR, Up to 24 months|Phase 1 and 2: Overall survival (OS), Time from the first dose of BA3021 treatment until death due to any cause, Up to 24 months|Phase 1 and 2: Tumor size, Percent change from baseline in tumor size, Up to 24 months",,"BioAtla, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,132,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,BA3021-001,2018-06-27,2024-12-30,2024-12-30,2018-04-20,,2025-03-25,"University of Arizona Cancer Center, Tucson, Arizona, 85724, United States|City of Hope - Duarte, Duarte, California, 91010, United States|University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California, 92093, United States|California Research Institute, Los Angeles, California, 90027, United States|USC Norris, Los Angeles, California, 90033, United States|UC Irvine Medical Center - Chao Family Comprehensive Cancer Center, Orange, California, 92868, United States|University of California San Francisco, San Francisco, California, 94158, United States|American Institute of Research, Whittier, California, 90603, United States|University of Colorado, Aurora, Colorado, 80045, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, 80218, United States|Florida Cancer Specialists & Research Institute, Fleming Island, Florida, 32003, United States|Florida Cancer Specialists & Research Institute, Fort Myers, Florida, 33916, United States|Memorial Cancer Institute (MCI), Hollywood, Florida, 33028, United States|Florida Cancer Specialist - North, Saint Petersburg, Florida, 34474, United States|Memorial Sloan-Kettering Cancer Center, Tampa, Florida, 33612, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Florida Cancer Specialists, West Palm Beach, Florida, 33401, United States|Augusta University - Georgia Cancer Center, Augusta, Georgia, 30912, United States|Baptist Health Systems, Lexington, Kentucky, 40503, United States|University of Kentucky, Lexington, Kentucky, 40536, United States|Norton Cancer Institute, Brownsboro Hospital Campus, Louisville, Kentucky, 40241, United States|Hematology/Oncology Clinic, Baton Rouge, Louisiana, 70809, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Comprehensive Cancer Care of Nevada, Las Vegas, Nevada, 89169, United States|OptumCare Cancer Care, Las Vegas, Nevada, 89169, United States|Roswell Park, Buffalo, New York, 14263, United States|NYU Langone Health, New York, New York, 10016, United States|Columbia University Medical Center, New York, New York, 10032, United States|FirstHealth Outpatient Cancer Center, Pinehurst, North Carolina, 28374, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, 27157, United States|The Christ Hospital, Cincinnati, Ohio, 45219, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|Medical University of South Carolina- Hollings Cancer Center, Charleston, South Carolina, 29407, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|Mary Crowley Cancer Research, Dallas, Texas, 75230, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|HENRY DUNANT Hospital Center, 4th Department of Medical Oncology and Clinical Trials Unit, Athens, 11526, Greece|Metropolitan Hospital ""Perseus Healthcare Group SA"" 4th Oncology Department, Piraeus, 18547, Greece|Bioclinic Thessaloniki, Οncology Department, Thessaloniki, 54622, Greece|European Interbalkan Medical Center, Οncology Department, Thessaloniki, 57001, Greece|Prince of Wales Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Polish Mother's Memorial Hospital-Research Institute, Lodz, Lodzkie, 93-338, Poland|Beata Głogowska, Tomaszów Mazowiecki, Lodzkie, 97-200, Poland|Institute of Genetics and Immunology GENIM LCC in Lublin, Lublin, Lubelskie, 20-609, Poland|Malgorzata Kozlik, Warsaw, Mazowieckie, 08-781, Poland|MED-Polonia, Sp. z o.o. (LLC), Poznan, Wielkopolskie, 60-693, Poland|University Hospital Nuestra Senora de Valme, Sevilla, Andalusia, 41014, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, 08041, Spain|Hospital del Mar, Barcelona, Catalonia, 089003, Spain|Anna Ramos Luna, Barcelona, Catalonia, 08908, Spain|University Clinic of Navarra - Madrid, Madrid, 28027, Spain|University Hospital 12 de Octubre, Madrid, 28041, Spain|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|LinKou Chang Gung Memorial Hospital, Taoyuan City, Taiwan",
